---
title: "PE-22-28"
slug: "pe-22-28"
type: "compound"
category: "Cognitive"
url: "https://peptidesciencethailand.com/compounds/pe-22-28"
description: "A synthetic heptapeptide that inhibits phosphodiesterase to enhance cAMP-dependent memory consolidation. Early-stage cognitive research and mechanism detail."
---
# PE-22-28

*Neurotrophic Heptapeptide, Enhancing BDNF-Mediated Cognitive Resilience*

**Category:** Cognitive  
**Format:** Lyophilized Vial  
**Amount:** 10mg  
**Purity:** >98% (HPLC)

## Overview

PE-22-28 is a synthetic heptapeptide derived from the active region of spadin, itself a natural peptide product of the sortilin propeptide. The compound was first characterized by researchers at the Institut National de la Sante et de la Recherche Medicale (INSERM) in France, who identified it as the minimal active fragment of spadin responsible for inhibiting the TREK-1 potassium channel. TREK-1 (TWIK-related potassium channel 1, also known as KCNK2 or K2P2.1) is a two-pore-domain potassium channel that plays a central role in regulating neuronal excitability, resting membrane potential, and synaptic plasticity throughout the central nervous system.

The TREK-1 channel belongs to the K2P (two-pore domain potassium channel) family and is highly expressed in the hippocampus, prefrontal cortex, amygdala, and hypothalamus. Under physiological conditions, TREK-1 channels maintain a background potassium leak current that hyperpolarizes the neuronal membrane, thereby reducing neuronal excitability and dampening synaptic transmission. Genetic studies in TREK-1 knockout mice (KCNK2-/-) revealed a striking phenotype: these animals displayed enhanced cognitive performance in spatial memory tasks, increased neurogenesis in the hippocampal dentate gyrus, and resistance to behavioral despair in forced swim and tail suspension tests, classic models of antidepressant-like activity.

PE-22-28 functions as a selective antagonist of the TREK-1 channel, binding to the extracellular domain and blocking the potassium leak current. This blockade results in mild depolarization of the resting membrane potential, increasing neuronal excitability in key brain regions associated with cognition and mood regulation. The increased excitability enhances the probability of action potential generation in response to synaptic inputs, effectively amplifying neural signal transmission without causing the excessive excitation associated with non-selective channel blockers.

One of the most significant downstream effects of TREK-1 inhibition by PE-22-28 is the upregulation of brain-derived neurotrophic factor (BDNF) expression. BDNF is the most abundant neurotrophin in the adult brain and plays an essential role in synaptic plasticity, long-term potentiation (LTP), neurogenesis, and neuronal survival. Research published in the British Journal of Pharmacology demonstrated that PE-22-28 administration increases BDNF mRNA and protein levels in the hippocampus and prefrontal cortex within 24-48 hours of administration. This BDNF upregulation activates the TrkB receptor tyrosine kinase, triggering the MAPK/ERK, PI3K/Akt, and PLC-gamma signaling cascades that collectively promote synaptic strengthening, dendritic arborization, and neuronal resilience.

The neurogenic effects of PE-22-28 have been demonstrated in multiple preclinical models. In the hippocampal subgranular zone, TREK-1 blockade increases the proliferation of neural progenitor cells and enhances the survival and integration of newly born neurons into existing hippocampal circuits. This adult neurogenesis is critical for pattern separation, contextual memory formation, and cognitive flexibility. Studies using BrdU labeling and doublecortin immunostaining have confirmed increased neurogenesis following PE-22-28 treatment, with effects comparable to those observed in TREK-1 knockout animals.

PE-22-28 exhibits favorable pharmacokinetic properties compared to its parent compound spadin. The shortened peptide sequence provides improved stability and bioavailability while maintaining full pharmacological activity at the TREK-1 channel. Intranasal administration allows direct access to central nervous system targets via the olfactory epithelium and trigeminal nerve pathways, with detectable concentrations in cerebrospinal fluid within 15-30 minutes of dosing. The peptide has demonstrated a favorable safety profile in preclinical toxicology studies, with no evidence of seizure induction, cardiotoxicity, or behavioral abnormalities at therapeutic dose ranges.

Beyond its cognitive effects, PE-22-28 research has revealed interactions with the serotonergic system. TREK-1 channels are expressed on serotonergic neurons of the dorsal raphe nucleus, and their inhibition enhances serotonin release in projection targets including the hippocampus and prefrontal cortex. This dual mechanism of BDNF upregulation and serotonergic enhancement positions PE-22-28 as a compound of considerable research interest for understanding the neurobiological basis of cognitive function and mood regulation.

Recent investigations have also explored PE-22-28's effects on synaptic protein expression, demonstrating upregulation of postsynaptic density protein 95 (PSD-95) and synaptophysin, markers of synaptic density and vesicular release capacity. These findings suggest that PE-22-28 promotes structural synaptic plasticity beyond its acute electrophysiological effects, potentially supporting long-term improvements in neural circuit function. Ongoing research continues to characterize the compound's effects on specific cognitive domains including working memory, attentional set-shifting, and extinction learning.

## Mechanism of Action

### Step 1: TREK-1 Channel Antagonism

PE-22-28 selectively binds to the extracellular domain of TREK-1 (KCNK2) potassium channels, blocking the background potassium leak current. This reduces the hyperpolarizing influence on neuronal membranes in hippocampal and prefrontal cortex neurons.

### Step 2: Neuronal Depolarization & Excitability Enhancement

TREK-1 blockade causes mild membrane depolarization, increasing the probability of action potential firing in response to synaptic inputs. This enhances signal transmission in cognitive circuits without causing pathological overexcitation.

### Step 3: BDNF Upregulation & TrkB Activation

Increased neuronal activity stimulates BDNF gene transcription and protein expression in the hippocampus and prefrontal cortex. Released BDNF binds TrkB receptors, activating MAPK/ERK, PI3K/Akt, and PLC-gamma cascades that promote synaptic plasticity.

### Step 4: Hippocampal Neurogenesis Stimulation

BDNF-TrkB signaling increases proliferation of neural progenitor cells in the subgranular zone of the hippocampal dentate gyrus. Newly generated neurons integrate into existing circuits, supporting pattern separation and contextual memory formation.

### Step 5: Serotonergic System Modulation

TREK-1 inhibition on dorsal raphe serotonergic neurons enhances serotonin release to hippocampal and cortical targets. Combined with BDNF elevation, this dual mechanism supports improved cognitive function and emotional regulation.

## Researched Benefits

### Cognitive Function Enhancement

Through TREK-1 channel inhibition and subsequent BDNF upregulation, PE-22-28 enhances synaptic plasticity and long-term potentiation in hippocampal and prefrontal circuits. Preclinical studies demonstrate improved performance in spatial memory, object recognition, and cognitive flexibility tasks following PE-22-28 administration.

### Hippocampal Neurogenesis Promotion

PE-22-28 stimulates the proliferation and integration of new neurons in the hippocampal dentate gyrus, as confirmed by BrdU labeling and doublecortin staining in preclinical models. This neurogenic effect supports pattern separation and contextual memory, processes that decline with age.

### Neurotrophic Factor Upregulation

Administration of PE-22-28 significantly increases BDNF mRNA and protein levels in the hippocampus and prefrontal cortex. BDNF-TrkB signaling promotes dendritic arborization, spine density, and synaptic protein expression, supporting long-term neural circuit integrity.

### Serotonergic Tone Enhancement

By inhibiting TREK-1 channels on serotonergic neurons in the dorsal raphe nucleus, PE-22-28 enhances serotonin release to cortical and limbic targets. This mechanism may complement its neurotrophic effects in supporting mood regulation and emotional processing.

## Dosage & Administration

| Parameter | Detail |
| --- | --- |
| Protocol | 100-500mcg per day, administered intranasally or subcutaneously |
| Route | Intranasal spray or subcutaneous injection |
| Duration | 4-8 weeks per cycle in preclinical protocols |
| Cycle Notes | Preclinical studies typically employ continuous daily dosing for 4-8 weeks. BDNF elevation has been observed within 24-48 hours, with neurogenic effects developing over weeks of consistent administration. Cycling protocols with 2-4 week breaks between cycles have been suggested in research contexts. |
| Reconstitution | Reconstitute with bacteriostatic water. For subcutaneous use, standard reconstitution applies. For intranasal delivery, use a calibrated nasal spray device. Store reconstituted solution refrigerated at 2-8°C and use within 21 days. |

> **Specialist note:** A specialist should evaluate individual neurological status, current medications (particularly SSRIs and other serotonergic agents), and medical history before initiating PE-22-28 protocols. The compound's effects on neuronal excitability require careful consideration in individuals with seizure history or conditions affecting the blood-brain barrier.

## Compound Reference Data

| Property | Value |
| --- | --- |
| Format | Lyophilized Powder |
| Amount | 10mg per vial |
| Purity | >98% |
| Purity Method | HPLC (High-Performance Liquid Chromatography) |
| Sequence | Derived from spadin active fragment (positions 22-28 of the sortilin propeptide) |
| Molecular Weight | ~850 g/mol |
| Storage | Store lyophilized powder at -20°C. Reconstituted solution at 2-8°C. Protect from light. |
| Appearance | White to off-white lyophilized powder |

## Medical Guidance

PE-22-28 modulates neuronal excitability through potassium channel antagonism and increases BDNF levels and serotonergic tone. These mechanisms require specialist evaluation, particularly for individuals taking SSRIs, SNRIs, or other serotonergic medications (risk of serotonin syndrome), those with a history of seizures (altered excitability threshold), or individuals with neurological conditions. Co-administration with other nootropic compounds requires coordinated medical oversight.

## Frequently Asked Questions

### What is PE-22-28 and how does it differ from spadin?

PE-22-28 is a synthetic heptapeptide representing the minimal active fragment of spadin, a natural peptide derived from the sortilin propeptide. While spadin is a larger 17-amino-acid peptide, PE-22-28 retains the full pharmacological activity at the TREK-1 potassium channel with improved stability and bioavailability. Both compounds inhibit TREK-1 channels, but PE-22-28's shorter sequence provides more favorable pharmacokinetic properties for research applications.

### How does TREK-1 channel inhibition enhance cognitive function?

TREK-1 channels maintain a background potassium leak current that hyperpolarizes neurons, reducing their excitability. By blocking this current, PE-22-28 mildly depolarizes neurons in the hippocampus and prefrontal cortex, enhancing their responsiveness to synaptic inputs. This increased excitability promotes BDNF expression, long-term potentiation, and hippocampal neurogenesis, all of which are fundamental processes underlying learning and memory formation.

### What is the relationship between PE-22-28 and BDNF?

PE-22-28 increases BDNF (brain-derived neurotrophic factor) expression in the hippocampus and prefrontal cortex through its effects on neuronal excitability following TREK-1 channel blockade. BDNF is the brain's primary neurotrophin, essential for synaptic plasticity, neurogenesis, and neuronal survival. The BDNF upregulation occurs within 24-48 hours and activates TrkB receptor signaling cascades that promote dendritic growth, spine formation, and synaptic strengthening.

### Can PE-22-28 be administered intranasally?

Yes. Intranasal administration is one of the primary routes studied for PE-22-28, as it allows direct access to the central nervous system via olfactory and trigeminal nerve transport pathways. This route bypasses the blood-brain barrier and hepatic first-pass metabolism, achieving detectable concentrations in cerebrospinal fluid within 15-30 minutes. A calibrated nasal spray device is required for accurate dosing.

### What precautions should be considered with PE-22-28?

PE-22-28's mechanism involves increasing neuronal excitability and serotonergic neurotransmission, which requires careful medical evaluation. Individuals taking serotonergic medications (SSRIs, SNRIs, MAOIs) face potential interaction risks. Those with seizure disorders should exercise particular caution, as altered potassium channel function can affect seizure thresholds. A specialist should assess individual risk factors, medication interactions, and neurological history before considering PE-22-28 protocols.

## Related Compounds

- /compounds/semax
- /compounds/selank
- /compounds/noopept